Recent study reports that EZH2 inhibitor EPZ-6438 triggers malignant pleural mesothelioma cells to express high level of different monocytes chemoattractants, including CCL2 and CSF1, which lead to increased monocytes recruitment in tumor spheroids as well as M2 TAMs differentiation [59]. Here, EZH2 is linked to pleural mesothelioma.